Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of breast cancer-related lymphedema with tacrolimus
2018-003416-50Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Oct 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tacrolimus in breast cancer-related lymphedema (BCRL), sponsored by University Hospital Odense. Primary endpoint: Feasibility of tacrolimus ointment use. Started Oct 2018; status: completed.
02
Drugs
tacrolimus
03
Conditions
breast cancer-related lymphedema (BCRL)
Beyond the preview
Go deeper on 2018-003416-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003416-50.